Tehran Lipid and Glucose Study: A National Legacy

authors:

avatar Fereidoun Azizi ORCID 1 , *

Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

how to cite: Azizi F. Tehran Lipid and Glucose Study: A National Legacy. Int J Endocrinol Metab. 2018;16(4 (Suppl)):e84774. https://doi.org/10.5812/ijem.84774.

References

  • 1.

    Ghassemi H, Harrison G, Mohammad K. An accelerated nutrition transition in Iran. Public Health Nutr. 2002;5(1A):149-55. [PubMed ID: 12027278]. https://doi.org/10.1079/PHN2001287.

  • 2.

    Sarrafzadegan N, Najafian J. Priorities in cardiovascular prevention in Iran. Iran Heart J. 1998;1(1):131.

  • 3.

    Azizi F, Gouya MM, Vazirian P, Dolatshahi P, Habibian S. The diabetes prevention and control programme of the Islamic Republic of Iran. East Mediterr Health J. 2003;9(5-6):1114-21. [PubMed ID: 16450545]. https://doi.org/10.1007/s000380200008.

  • 4.

    Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed. 2002;47(6):408-26. [PubMed ID: 12643001].

  • 5.

    Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10:5. [PubMed ID: 19166627]. [PubMed Central ID: PMC2656492]. https://doi.org/10.1186/1745-6215-10-5.

  • 6.

    Azizi F. Tehran lipid and glucose study: A legacy for prospective community-based research. Arch Iran Med. 2014;17(6):392-3. [PubMed ID: 24916522].

  • 7.

    Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A, et al. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. Am J Prev Med. 2010;38(6):628-636 e1. [PubMed ID: 20494239]. https://doi.org/10.1016/j.amepre.2010.03.003.

  • 8.

    Azizi F, Mirmiran P, Momenan AA, Hadaegh F, Habibi Moeini A, Hosseini F, et al. The effect of community-based education for lifestyle intervention on the prevalence of metabolic syndrome and its components: tehran lipid and glucose study. Int J Endocrinol Metab. 2013;11(3):145-53. [PubMed ID: 24348586]. [PubMed Central ID: PMC3860109]. https://doi.org/10.5812/ijem.5443.

  • 9.

    Wong ND, Levy D. Legacy of the framingham heart study: Rationale, design, initial findings, and implications. Glob Heart. 2013;8(1):3-9. [PubMed ID: 25690260]. https://doi.org/10.1016/j.gheart.2012.12.001.

  • 10.

    Mirbolouk M, Derakhshan A, Charkhchi P, Guity K, Azizi F, Hadaegh F. Incidence and predictors of early adulthood pre-diabetes/type 2 diabetes, among Iranian adolescents: The Tehran Lipid and Glucose Study. Pediatr Diabetes. 2016;17(8):608-16. [PubMed ID: 26764014]. https://doi.org/10.1111/pedi.12343.

  • 11.

    Daneshpour MS, Fallah MS, Sedaghati-Khayat B, Guity K, Khalili D, Hedayati M, et al. Rationale and design of a genetic study on cardiometabolic risk factors: Protocol for the Tehran Cardiometabolic Genetic Study (TCGS). JMIR Res Protoc. 2017;6(2). e28. [PubMed ID: 28232301]. [PubMed Central ID: PMC5344981]. https://doi.org/10.2196/resprot.6050.

  • 12.

    Azizi F. Precision medicine for endocrinology. Int J Endocrinol Metab. 2016;14(3). e40283. [PubMed ID: 28115967]. [PubMed Central ID: PMC5219894]. https://doi.org/10.5812/ijem.40283.